Washington D.C., Oct 23, 2023- Global Alzheimer’s Platform Foundation, (GAP) is pleased to share that new data from the ground-breaking blood-based and digital biomarker platform study, Bio-Hermes, will be shared by study partner Dr. Robin Wolz, of IXICO, at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) conference. The data will be presented at Symposium #1 of the conference. The conference will be held in Boston, Massachusetts, United States and virtually from October 24 to 27, 2023.
Symposium #1- The Effects of Race and Gender on Amyloid Positivity
Presentation 1: Amyloid PET results from the GAP Bio-Hermes study: initial findings on differences between racial and ethnic groups
In the opening symposium on October 24 at 4:55 EST, IXICO will present the latest data from the GAP-sponsored blood-based and digital biomarker platform study, Bio-Hermes. Bio-Hermes is a first-of-its-kind study comparing 15 digital tests and 35 blood-based biomarkers to evaluate their ability to better measure cognitive impairment or beta-amyloid plaques when compared with an amyloid PET scan. The presentation will include the analysis of the relationship between these tests to enhance the field’s ability to provide a more economical, timely, and accurate diagnosis of Alzheimer’s Disease. The presentation will also include discussion on how this study enriches the dataset with robust genomic and proteomic profiles of the 1,001 participants enrolled in the study.
Richard Mohs, Ph.D., Lynne Hughes, Ph.D., PMP, John Dwyer, and Douglas Beauregard from GAP will be present as Robin Wolz, Ph.D., and Richard Manber Ph.D., of IXICO discuss their findings.
“The Bio-Hermes data informs the discussion on whether there are material differences between racial or ethnic groups in terms of how they demonstrate amyloid plaque accumulation. We expect that our rigorous work with IXICO in generating a well-characterized set of PET images and associated biomarkers across a diverse study population will accelerate our understanding of how to diagnose Alzheimer’s and anticipate the progression of the disease,” said John Dwyer, President of Global Alzheimer’s Platform Foundation. “We owe it to patients to put their minds at ease that the diagnostic process and Alzheimer’s therapies work for everybody–Bio-Hermes’ data helps the field meet that obligation.”
In addition to Symposium #1, GAP will present data and research with two poster presentations.
Research Overview
Bio-Hermes study topline results: Aß 40/42 and p-tau 181/217/231 blood-based biomarkers compared to amyloid PET and CSF in a diverse, community-based population
- Date and time: Wednesday, October 25-Friday, October 27; 7:30am to 8:30 am EST
- Presented by: Douglas Beauregard, Project Director, Clinical Operations, Global Alzheimer’s Platform Foundation
Apheleia- Improving Diverse Recruitment in an Early Phase Therapeutic AD trial through a Pre-Screening Study, Apheleia-001
- Date and time: Wednesday, October 25 8:00 am to 6:00 pm EST
- Presented by: Leigh Zisko, CCRP, Vice President, Trial Recruitment and Study Solutions, Global Alzheimer’s Platform Foundation
For more information on GAP, visit https://globalalzplatform.org/.
—END—
About GAP
The Global Alzheimer’s Platform Foundation® (GAP) is a patient-centered nonprofit organization dedicated to accelerating the delivery of innovative therapies for neurological disorders by reducing the duration and cost of clinical trials. Over 100 research centers around the world are part of the growing GAP Network (GAP-Net).